Indianapolis-based Lilly announced today that it’s pleaded guilty to a charge that it illegally marketed the anti-psychotic Zyprexa. The company will pay $1.42 billion to the federal government and to about 30 states to settle civil suits and end the criminal investigation.
Maine Attorney General Janet Mills said the state will get more than $1.3 million to reimburse MaineCare for the costs associated with Lilly’s activities.
Lilly’s plea states that the company marketed the drug for dementia, including Alzheimer’s-related dementia, even though the drug isn’t approved for that use.
The company isn’t acknowledging any wrongdoing in the civil case.